In:
Journal of Gastroenterology and Hepatology, Wiley, Vol. 35, No. 7 ( 2020-07), p. 1247-1253
Abstract:
The most common adverse event following an endoscopic retrograde cholangiopancreatography (ERCP) procedure is post‐ERCP pancreatitis (PEP). Rectal nonsteroidal anti‐inflammatory drug (NSAID) administration has shown promise to reduce the risk of PEP in high‐risk patients. However, in contrast to high‐risk patients, the role of NSAID administration in patients with low risk remains controversial. Methods We performed a prospective, single‐center, single‐blinded, two‐arm parallel group, randomized controlled trial to clarify the efficacy of low dose (50 mg) rectal NSAID administration for preventing PEP in at‐risk patients. Patients scheduled to undergo ERCP were randomized into two groups, those with and without rectal administration of diclofenac. Patients in the diclofenac group received 50 mg of rectal diclofenac 30 min before undergoing ERCP. The primary endpoint was rate of PEP. Results A total of 303 were randomized into the study groups. Four patients declined participation following randomization, and another two were withdrawn. As a result, a total of 147 patients were assigned to the diclofenac group and 150 to the control group. The baseline and procedural characteristics were similar in both groups. The primary endpoint of PEP occurrence was seen in 13 of 297 patients (4.4%), including eight (5.4%) in the diclofenac group and five (3.3%) in the control group ( P = 0.286). Additionally, those results were not significantly different when patients were classified as low or high risk. Conclusions Prophylactic low‐dose rectal diclofenac did not reduce the incidence of PEP following ERCP in patients classified as low or high risk.
Type of Medium:
Online Resource
ISSN:
0815-9319
,
1440-1746
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
2006782-3
